Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.58 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756494 | 0.88 | ELANE (0.73) | ELANENOTUM | |
| SCHEMBL31490303 | 0.84 | ELANE (0.48) | ELANENOTUMPLA2G10CYP1A2GSR | |
| SCHEMBL560944 | 0.84 | ELANE (0.48) | ELANENOTUMPLA2G10CYP1A2GSR | |
| SCHEMBL5445143 | 0.83 | PLA2G10 (0.56) | ELANENOTUMPLA2G10CYP1A2GSR | |
| SCHEMBL5759984 | 0.82 | ELANE (0.73) | ELANETP53PPARG | |
| SCHEMBL11895153 | 0.82 | NOTUM (0.47) | ELANENOTUMPLA2G10CYP1A2GSR | |
| SCHEMBL5755788 | 0.82 | ELANE (0.79) | ELANENOTUMMAPTPOLBLMNA | |
| SCHEMBL5757787 | 0.82 | ELANE (0.59) | ELANENOTUMMAPTPOLBNPY5R | |
| SCHEMBL561046 | 0.82 | NOTUM (0.68) | ELANENOTUMCYP1A2GSRMAPT | |
| SCHEMBL5758541 | 0.81 | ELANE (0.59) | ELANENOTUMPLA2G10CYP1A2GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885NOTUM 3748/4885PLA2G10 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.